KEY PROJECT PARTICIPANTS
MANUFACTURER/OWNER Bristol-Myers Squibb
38 Jackson Rd.
Devens, Massachusetts 01434 United States
ENGINEER/ARCHI TEC T (A&E) ARC/Architectural Resources Cambridge
501 Boylston St., Suite 4101
Boston, Massachusetts 02116 United States
Clark, Richardson & Biskup (CRB)
220 West Germantown Pike, Suite 170
Plymouth Meeting, Pennsylvania 19462 United States
CONSTRUC TION MANAGER Lendlease (US) Construction LMB Inc.
20 City Square, 2nd Floor
Boston, Massachusetts 02129 United States
STRUC TURAL ENGINEERS Symmes Maini & McKee Associates (SMMA)
1000 Massachusetts Ave.
Cambridge, Massachusetts 02138 United States
SNC-Lavalin Project Services, Inc.
436 Creamery Way #100
Exton, Pennsylvania 19341 United States
MAJOR EQUIPMEN T SUPPLIER GE Healthcare
3350 North Ridge Ave.
Arlington Heights, Illinois 60004 United States
99 High St., 10th Floor
Boston, Massachusetts 02110 United States
“When we were all there for the ribbon-cutting and we walked around with
the scientists, there was palpable excitement,” says Tereshak. “Employees
knew how important it was for them to interact with the other people in
the chain, going from process development all the way through commercial
Reflecting on the successful project, Jeffreys Johnson, AIA, Principal in
Charge at ARC, points to the collaboration between all the companies in-
volved. “We saw a lot of challenges, but if we hadn’t worked together so
closely and so well the challenges would have been much greater,” he says.
“But it was a very collaborative process from the start, and that really did
make it the successful project that it is.”
Ryan McDonough, Senior Associate, Biotechnology Core Team Leader at
CRB, sums up the project this way: “The CMB is one of a small number of fully
single-use manufacturing facilities in this industry. And one of the things that
we don’t want to lose sight of is the integration of discovery of potential new
medicines through commercial manufacturing to get the medications to the
patient. Having that all on one campus is pretty important.” ‹›
“ONE OF THE THINGS
WE DON’T WANT TO
LOSE SIGHT OF IS
THE INTEGRATION OF
POTENTIAL NEW MEDICINES
MANUFACTURING TO GET
THE MEDICATIONS TO